The other groups revealed lesser rates with 30.4% (n = 162) in the hormone receptor positive and/or HER2-amplified breast cancer group, 25.0% (n = 1) in the male breast cancer group and 12.8% (n = 5) in the ductal carcinoma in situ group. Here, ERBB2 is linked to breast carcinoma.